Anonymous15 days ago
The FDA approved Wegovy HD, a 7.2 mg dose of semaglutide that triples the previous maximum and delivers roughly 21% average weight loss over 72 weeks—but the approval raises questions about long-term safety, medication dependency, and whether the higher dose is primarily a clinical advance or a competitive and patent strategy by Novo Nordisk. With over 70% of trial participants experiencing gastrointestinal side effects, limited long-term safety data, and significant weight regain upon discontinuation, the approval highlights the tension between expanding treatment options for obesity and the commercial imperatives driving GLP-1 drug development.